Dementia (umbrella)
Dementia is an umbrella term for changes that affect thinking, memory, communication, and everyday tasks. It is not a normal part of ageing.
Overview
Dementia names a syndrome: acquired, progressive difficulty with cognition that interferes with daily life. Alzheimer’s disease is the most discussed cause on this atlas, but vascular injury, Lewy body disease, frontotemporal degeneration, Parkinson’s disease, and mixed pathology also cause dementia. Mild cognitive impairment is a related state in which changes are noticeable but daily independence is largely preserved. Labels help match care, trials, and medicines. They do not replace a clinical assessment.
- Memory, language, visuospatial, or judgement changes that interfere with daily tasks.
- Changes are acquired and usually progressive, not a lifelong learning difference.
- A clinician takes a history from the person and someone who knows them, reviews medicines, and looks for reversible contributors.
- Further tests are chosen for the individual, not as a fixed panel.
- Care needs are often described as early, moderate, or severe. These are support descriptions, not a single lab number.
State of the art
- Diagnosis is clinical first, with biomarkers used to support subtype questions rather than to replace the story of the person.
- Care planning, safety, and carer support sit beside any medicine discussion.
Dementia is a clinical syndrome, not a single disease. Several brain diseases can cause it, and mixed pathology is common.
Open problems
- Many people never receive a subtype diagnosis.
- Trial populations still under-represent mixed pathology, vascular disease, and diverse communities.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
History, examination, medicines review, blood tests for reversible contributors, and cognitive testing. Imaging and specialist referral follow local pathways.
Subtypes & biomarkers
top- Clinical history and informant report
- Cognitive testing
- Structural MRI
- Amyloid PET or cerebrospinal fluid amyloid and tau where indicated
- Blood biomarker research assays
Dated changes read from the records linked to this diagnosis: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 1 changes by month →What is in development for Dementia (umbrella), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this diagnosis, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Technologies being tested · 1
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Who & centres
topOrganisations and centres
This atlas lists sourced companies, institutions, and public figures — not a “see this doctor” directory. Start from Who or the institutions index, and ask the person’s clinical team about a memory clinic referral.
No institutions are linked to this diagnosis yet.
For urgent help and helplines, see resources.
Questions to ask
topQuestions to ask your clinician about Dementia
Newly diagnosed
- What is my exact diagnosis, and which assessments established it?Why: Care plans follow from an accurate diagnosis and how it was confirmed.
- Which biomarkers or tests have been done (for example Clinical history and informant report, Cognitive testing, Structural MRI, Amyloid PET or cerebrospinal fluid amyloid and tau where indicated, Blood biomarker research assays), and what were the results?Why: These results can support the diagnosis and eligibility for some treatments or trials.
- Which subtype or related condition best fits my case, and does that change the recommended care?Why: Recognised subtypes for this diagnosis include Alzheimer’s disease, Dementia with Lewy bodies, Parkinson’s disease dementia.
- Is genetic testing recommended for me or my family, and what counselling comes with it?Why: Inherited variants can change counselling and, rarely, care; they matter for relatives too.
Any suspected dementia
- For my situation (any suspected dementia), which of the standard options do you recommend and why?Why: Guideline options include: History, examination, medicines review, blood tests for reversible contributors, and cognitive testing. Imaging and specialist referral follow local pathways.
Any stage
- Would a second opinion at a memory clinic or specialist centre change anything, and can you help arrange it?Why: Complex or high-stakes decisions benefit from a centre that sees many similar patients.
- What supportive care (symptom control, carer support, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps people stay on a plan that fits them.
- I read that “Many people never receive a subtype diagnosis”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Trial populations still under-represent mixed pathology, vascular disease, and diverse communities”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Start from the care guide for household next steps, and use resources for helplines.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this diagnosis's products.
fronts
2technologies
1terms
2bottlenecks
2Latest papers
topQuery for this diagnosis: (TITLE:"Dementia" OR ABSTRACT:"Dementia" OR TITLE:"umbrella" OR ABSTRACT:"umbrella") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Dementia (umbrella), not a curated reading list.
Similar pages
not linked directly; found by shared links- IdeaBlood test before PET or lumbar puncture
Shares Late and uneven diagnosis, Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentRivastigmine
Shares Parkinson’s disease dementia, Dementia with Lewy bodies, Alzheimer’s disease and the tag dementia-atlas.
- TargetAlpha-synuclein
Shares Parkinson’s disease dementia, Dementia with Lewy bodies and the tag dementia-atlas.
- TargetAcetylcholinesterase
Shares Parkinson’s disease dementia, Dementia with Lewy bodies, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyBrain MRI
Shares Vascular dementia, Alzheimer’s disease and the tag dementia-atlas.
- BottleneckTrial populations that skip mixed disease
Shares Mixed dementia, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyBlood Alzheimer biomarkers
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- BottleneckUnpaid care as the hidden delivery system
Shares Dementia care navigation and the tag dementia-atlas.